May 6th 2022
Investigators presented up to 2 years of post-marketing data on the first-ever gene therapy.
May 5th 2022
Updated data at ARVO show that AGTC-501 had sustained efficacy and safety at 18 months for patients with X-linked retinitis pigmentosa caused by RPGR mutations.
Veeral S. Sheth, MD, MBA, Director of Clinical Research at the University of Retina and Macula Associates, discusses advanced therapies for retinal diseases.
May 2nd 2022
New data from cohort 4 showed outer retinal restoration following treatment with OpRegen.
The post-hoc analysis of the OPTIC trial explored the effects of neutralizing antibodies on patients treated with ADVM-002.
May 3rd 2021
The single-injection investigative gene therapy may help with providing continuous expression of aflibercept.
The AAV8 vector–based gene therapy was associated with improvements in 2 measures of visual function.
Optical coherence tomography characteristics may be predictive of the efficacy of intravitreal injection of allogeneic human retinal progenitor cells, according to research presented at ARVO 2021.